On Monday, Jones Trading maintained its Buy rating and $20.00 price target for Rallybio Corp. (NASDAQ: RLYB). The firm's stance comes in light of Rallybio's recent announcement regarding an epidemiology analysis of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). According to the analysis, the condition may be more prevalent in at-risk pregnancies than previously understood, especially among non-Caucasian populations.
Rallybio is preparing to commence a Phase 2 trial for its leading asset, RLYB212, which is designed to address FNAIT. The company expects to present the full epidemiology data at a medical meeting scheduled for 2024. This development follows a strategic equity investment by Johnson & Johnson (NYSE:JNJ) (Not Rated) in Rallybio, aimed at capitalizing on Rallybio's expertise for the Phase 3 trial of nipocalimab in treating FNAIT.
The analyst's reiteration of the Buy rating and the $20.00 price target reflects a positive outlook on Rallybio's prospects, particularly regarding its RLYB212 asset. The anticipation for the upcoming Phase 2 trial and the interest from a major pharmaceutical company like Johnson & Johnson underscore the potential of Rallybio's work in the FNAIT therapeutic area.
Rallybio's focus on developing treatments for rare diseases has garnered significant attention, and the latest findings from their epidemiology analysis could have implications for the scope of RLYB212's use. With the Phase 2 trial on the horizon, Rallybio is positioned to further its research and development in a niche yet critical medical field.
In other recent news, Rallybio Corp. has seen significant developments. JPMorgan (NYSE:JPM) has downgraded Rallybio's stock from Overweight to Neutral, citing a lack of near-term catalysts in 2024. Analysts at the firm recognize the long-term value of Rallybio's lead asset, RLYB212, intended for the treatment of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), with a phase 2 trial scheduled to begin in the second half of 2024. However, they suggest more upside could be expected in 2025 or 2026 as the phase 2 study progresses.
In addition, Rallybio has announced a partnership with Johnson & Johnson to advance treatments for FNAIT. The collaboration involves a $6.6 million equity investment from Johnson & Johnson Innovation – JJDC, Inc. into Rallybio. Johnson & Johnson will also fund awareness initiatives for FNAIT in conjunction with Rallybio's ongoing study of the disease's natural history.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.